Mechanistic contribution of carnitine deficiency to geriatric frailty

Ageing Research Reviews

Volumn 9, Issue 3, 2010, Pages 265-268

  Crentsil, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Carnitine; Frailty; Mitochondrion

Indexed keywords

CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE II; ORGANIC CATION TRANSPORTER 2; PLACEBO; UNCLASSIFIED DRUG;

AGING; CARNITINE DEFICIENCY; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG RESEARCH; ENERGY METABOLISM; FATIGUE; FRAIL ELDERLY; GENE MUTATION; GERIATRIC DISORDER; HUMAN; MITOCHONDRIAL MYOPATHY; MUSCLE ATROPHY; MUSCLE FATIGUE; MUSCLE LEVEL; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; PATHOGENESIS; REVIEW; SKELETAL MUSCLE;

AGED; AGED, 80 AND OVER; AGING; CARNITINE; FRAIL ELDERLY; HUMANS; VITAMIN B DEFICIENCY;

EID: 77952546637     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.02.005     Document Type: Review

References (45)

1. Angelini C., Trevisan C., Isaya G., Pegolo G., and Vergani L. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clin. Biochem. 20 (1987) 1-7
2. Barrientos A., Casademont J., Cardellach F., Ardite E., Estivill X., Urbano-Marquez A., et al. Qualitative and quantitative changes in skeletal muscle mtDNA and expression of mitochondrial-encoded genes in the human aging process. Biochem. Mol. Med. 62 (1997) 165-171
3. Bonnefont J.P., Demaugre F., Prip-Buus C., Saudubray J.M., Brivet M., Abadi N., and Thuillier L. Carnitine palmitoyltransferase deficiencies. Mol. Genet. Metab. 68 (1999) 424-440
4. Bowyer B.A., Fleming C.R., Ilstrup D., Nelson J., Reek S., and Burnes J. Plasma carnitine levels in patients receiving home parenteral nutrition. Am. J. Clin. Nutr. 43 (1986) 85-91
5. Brass E.P., Adler S., Sietsema K.E., Hiatt W.R., Orlando A.M., Amato A., et al. Intravenous l-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am. J. Kidney Dis. 37 (2001) 1018-1028
6. Buchner D.M., and Wagner E.H. Preventing frail health. Clin. Geriatr. Med. 8 (1992) 1-17
7. Calabrese V., Giuffrida Stella A.M., Calvani M., and Butterfield D.A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J. Nutr. Biochem. 17 (2006) 73-88
8. Campos Y., Huertas R., Bautista J., Gutierrez E., Aparicio M., Lorenzo G., et al. Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy. Muscle Nerve 16 (1993) 778-781
9. Campos Y., Huertas R., Lorenzo G., Bautista J., Gutierrez E., Aparicio M., et al. Plasma carnitine insufficiency and effectiveness of l-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 16 (1993) 150-153
10. Campos Y., Arenas J., Cabello A., and Gomez-Reino J.J. Respiratory chain enzyme deficiency in patients with idiopathic inflammatory myopathy. Ann. Rheum. Dis. 54 (1995) 491-493
11. Cederbaum S.D., Koo-McCoy S., Tein I., Hsu B.Y., Ganguly A., Vilain E., et al. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol. Genet. Metab. 77 (2002) 195-201
12. Costell M., O'Connor J.E., and Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem. Biophys. Res. Commun. 161 (1989) 1135-1143
13. Dirks A.J., Hofer T., Marzetti E., Pahor M., and Leeuwenburgh C. Mitochondrial DNA mutations, energy metabolism and apoptosis in aging muscle. Ageing Res. Rev. 5 (2006) 179-195
14. Ensrud K.E., Ewing S.K., Taylor B.C., et al. Frailty and the risk of falls, fracture, and mortality in older women: the study of osteoporosis fractures. J. Gerontol. A Biol. Sci. Med. Sci. 62 (2007) 744-751
15. Famularo G., de Simone C., Trinchieri V., and Mosca L. Carnitine and its congeners. A metabolic pathway to the regulation of immune response and inflammation. Ann. N. Y. Acad. Sci. 1033 (2004) 132-138
16. Franceschi C., Cossarizza A., Troiano L., Salati R., and Monti D. Immunological parameters in aging: studies on natural immunomodulatory and immunoprotective substances. Int. J. Clin. Pharmacol. Res. 10 (1990) 53-57
17. Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56 (2001) M146-M156
18. Fried L.P., Ferrucci L., Darer J., Williamson J.D., and Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J. Gerontol. A Biol. Sci. Med. Sci. 59 (2004) 255-263
19. Gonzalez-Crespo M.R., Arenas J., Gomez-Reino J.J., Campos Y., Borstein B., Martin M.A., et al. Muscle dysfunction in elderly individuals with hip fracture. J. Rheumatol. 26 (1999) 2229-2232
20. Heuberger W., Berardi S., Jacky E., Pey P., and Krahenbuhl S. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur. J. Clin. Pharmacol. 54 (1998) 503-508
21. Jogl G., Hsiao Y.S., and Tong L. Structure and function of carnitine acyltransferases. Ann. N. Y. Acad. Sci. 1033 (2004) 17-29
22. Karin M., and Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57 (2005) 283-295
23. Karlic H., Lohninger A., Laschan C., Lapin A., Bohmer F., Huemer M., et al. Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. J. Mol. Med. 81 (2003) 435-442
24. Karmaniolas K., Ioannidis P., Liatis S., Dalamanga M., Papalambros T., and Migdalis I. Primary carnitine deficiency in a male adult. J. Med. 33 (2002) 105-110
25. Kumaran S., Subathra M., Balu M., and Panneerselvam C. Supplementation of l-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. Exp. Aging Res. 31 (2005) 55-67
26. Leng S.X., Cappola A.R., Andersen R.E., Blackman M.R., Koenig K., Blair M., et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin. Exp. Res. 16 (2004) 153-157
27. Malaguarnera M., Di Mauro A.P.A., and Gargante P.M. l-Carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med. J. 3 (2006) 315
28. Mikhail M.M., and Mansour M.M. The relationship between serum carnitine levels and the nutritional status of patients with schistosomiasis. Clin. Chim. Acta 71 (1976) 207-214
29. Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J. Child Neurol. 10 Suppl: S (1995) 40-44
30. Pertosa G., Grandaliano G., Simone S., Soccio M., and Schena F.P. Inflammation and carnitine in hemodialysis patients. J. Ren. Nutr. 15 (2005) 8-12
31. Pistone G., Marino A., Leotta C., Dell'Arte S., Finocchiaro G., and Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 20 (2003) 761-767
32. Pons R., and De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J. Child Neurol. 10 Suppl 2 (1995) S8-S24
33. Rebouche C.J., and Engel A.G. Carnitine metabolism and deficiency syndromes. Mayo Clin. Proc. 58 (1983) 533-540
34. Rebouche C.J., and Paulson D.J. Carnitine metabolism and function in humans. Ann. Rev. Nutr. 6 (1986) 41-66
35. Savica V., Santoro D., Mazzaglia G., Ciolino F., Monardo P., Calvani M., et al. l-Carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J. Ren. Nutr. 15 (2005) 225-230
36. Savitha S., Sivarajan K., Haripriya D., Kokilavani V., and Panneerselvam C. Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging. Clin. Nutr. 24 (2005) 794-800
37. Stephens F.B., Constantin-Teodosiu D., and Greenhaff P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J. Physiol. 581 Part 2 (2007) 431-444
38. Tanphaichitr V., and Leelahagul P. Carnitine metabolism and human carnitine deficiency. Nutrition 9 (1993) 246-254
39. Urban T.J., Gallagher R.C., Brown C., et al. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol. Pharmacol. 70 (2006) 1602-1611
40. Vanitallie T.B. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism 52 (2003) 22-26
41. Vescovo G., Ravara B., Gobbo V., Sandri M., Angelini A., Della Barbera M., et al. l-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol. Cell. Physiol. 283 (2002) C802-C810
42. Vinci E., Rampello E., Zanolim L., Oreste G., Pistone G., and Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur. J. Intern. Med. 16 (2005) 419-423
43. Walston J., McBurnie M.A., Newman A., Tracy R.P., Kop W.J., Hirsch C.H., et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch. Intern. Med. 162 (2002) 2333-2341
44. Watanabe S., Ajisaka R., Masouka T., Yamanouchi T., Saitou T., Toyama M., et al. Effects of l- and dl-carnitine on patients with impaired exercise tolerance. Jpn. Heart J. 36 (1995) 319-331
45. Yaris N., Ceviz N., Coskun T., Akytuz C., and Buyukpamukcu M. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J. Exp. Clin. Cancer Res. 21 (2002) 165-170